ReviewPlant cell reports2012
Glycoprotein production in moss bioreactors.
Review in Plant cell reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Mass Spectrometric Analysis ofMolecules (Basel, Switzerland) · 2026Article
- Multiplication of peat moss (Sphagnum L.) species for climate action.Journal of experimental botany · 2026Review
- The Importance of thePlants (Basel, Switzerland) · 2026Review
- Molecular Pharming: Advances, Applications, and Future Prospects in Biotechnology and Medicine.Engineering in life sciences · 2026Review
- Recent advances and future directions on GLA-producing organisms.Frontiers in bioengineering and biotechnology · 2025Review
- Differential prolyl hydroxylation by six Physcomitrella prolyl-4 hydroxylases.Computational and structural biotechnology journal · 2024Article
- Production of Plant Proteins and Peptides with Pharmacological Potential.Advances in biochemical engineering/biotechnology · 2024Review
- Practical use of tobravirus-based vector to produce SARS-CoV-2 antigens in plants.Journal of virological methods · 2023Article
- The advent of plant cells in bioreactors.Frontiers in plant science · 2023Review
- Expression of a human cDNA in moss results in spliced mRNAs and fragmentary protein isoforms.Communications biology · 2021Article
- Stable Protein Sialylation in Physcomitrella.Frontiers in plant science · 2020Article
- Recombinant Production of MFHR1, A Novel Synthetic Multitarget Complement Inhibitor, in Moss Bioreactors.Frontiers in plant science · 2019Article
- Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems.Frontiers in plant science · 2019Review
- Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.Journal of the American Society of Nephrology : JASN · 2017Article
- Golgi-to-plastid trafficking of proteins through secretory pathway: Insights into vesicle-mediated import toward the plastids.Plant signaling & behavior · 2016Article
- Moss-made pharmaceuticals: from bench to bedside.Plant biotechnology journal · 2015Review
- Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs.Microbial cell factories · 2015Review
- An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice.Plant cell reports · 2015Article
- High contents of very long-chain polyunsaturated fatty acids in different moss species.Plant cell reports · 2014Article
- Protein N-glycosylation in eukaryotic microalgae and its impact on the production of nuclear expressed biopharmaceuticals.Frontiers in plant science · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complex multimeric recombinant proteins such as therapeutic antibodies require a eukaryotic expression system. Transgenic plants may serve as promising alternatives to the currently favored mammalian cell lines or hybridomas. In contrast to prokaryotic systems, posttranslational modifications of plant and human proteins resemble each other largely, among those, protein N-glycosylation of the complex type. However, a few plant-specific sugar residues may cause immune reactions in humans, representing an obstacle for the broad use of plant-based systems as biopharmaceutical production hosts. The moss Physcomitrella patens represents a flexible tissue-culture system for the contained production and secretion of recombinant biopharmaceuticals in photobioreactors. The recent synthesis of therapeutic proteins as a scFv antibody fragment or the large and heavily modified complement regulator factor H demonstrate the versatility of this expression system. A uniquely efficient gene targeting mechanism can be employed to precisely engineer the glycosylation machinery for recombinant products. In this way, P. patens lines with non-immunogenic optimized glycan structures were created. Therapeutic antibodies produced in these strains exhibited antibody-dependent cellular cytotoxicity superior to the same molecules synthesized in mammalian cell lines.
Indexed as
Identifiers
21960098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.